FDA warns Eniva USA over manufacturing quality failures for Immune Support and Ashwagandha Gummies.
What happened
FDA inspected Eniva USA's Plymouth, MN facility from November 19, 2024, through January 13, 2025, and reviewed product labels and the website. FDA found the firm did not establish finished-product specifications for identity, purity, strength, and composition and did not document material review and disposition decisions. FDA also said the firm's response on acid foods under 21 CFR 114.83 was inadequate.
What FDA found
Eniva USA did not establish finished-batch specifications that confirm the identity, purity, strength, and composition of its Immune Support and Ashwagandha Gummies supplements.
21 CFR 111.70(e)Eniva USA did not document investigations, findings, quality review, and disposition decisions for material review events.
21 CFR 111.140(b)(3)FDA found the firm's response about whether Vibe products are acid foods inadequate and asked for supporting documents, formulation, and pH information.
21 CFR 114.83
What FDA wants
FDA asks Eniva USA to notify it in writing within 15 working days of steps taken to address the violations, with explanations and documentation to prevent recurrence. If corrections cannot be completed in that time, the firm must state why and give a completion timeframe.
Who should pay attention
- dietary supplement manufacturers with similar finished-product specifications
- quality teams responsible for material review and disposition records
- brands selling acidified or acid-food beverages like Vibe
This is a summary. Read the original letter on fda.gov.